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THE ONCOGENIC MAP KINASE SIGNALING PATHWAY MODULATES MHC-I
SURFACE EXPRESSION IN MELANOMA

Sherille Denae Bradley, B.S.
Advisory Professor: Gregory A. Lizee, Ph.D.
The mitogen-activated protein kinase (MAPK) pathway is a cascade of serinethreonine kinases involved in cell growth, proliferation, and apoptosis; it is one of the most
well-known pathways associated with melanoma progression. The MAPK pathway is
constitutively activated in melanomas due to mutations in the signaling components,
V600E

particularly the proto-oncogene BRAF

that accounts for (40-50%) of these cases.

Metastatic melanoma is one of the deadliest and most aggressive forms of cancer, with a 3year survival rate of less than 15%. Immunotherapies that utilize cytotoxic T lymphocytes
(CTLs) have proven to be very effective at inducing regressions of large, bulky tumors, and
in improving melanoma patient survival. Two MAPK targeted inhibitors, vemurafenib and
dabrafenib, have produced positive results in clinical trials thus far, but they are not without
limitations. Recent studies have shown that oncogene activation in tumor cells can affect the
level of expression of major histocompatibility complex I molecules (MHC-I) on the cell
surface, and potentially allow melanoma cells to escape immune system surveillance. MHCI molecules expressed by tumor cells are the crucial targets recognized by CTLs to kill
tumor cells; thus, strategies to improve MHC-I antigen presentation to T-cells is very likely
to improve the efficacy of current immunotherapies. In DCs and other hematopoietic cell
types the rapid internalization and recycling of MHC-I through endocytic compartments has
been characterized as a cytoplasmic tail dependent process. The MHC-I cytoplasmic tail
iv

possesses two conserved phosphorylation sites, a tyrosine (Y320) and serine (S335). It is
known that MAPK pathway activation can induce a phosphorylation signaling cascade in
tumor cells, but the mechanism behind the regulation of MHC-I internalization and
modulation has yet to be identified in tumor cells.
In our study we show that both BRAF and MEK inhibitors increase MHC-I surface
V600E

expression in BRAF

melanoma mutant cell lines. Additional studies have shown that

the level of MHC-I surface expression directly affects CTL recognition and cytokine release.
We also reveal a novel potential mechanism for MAPK pathway regulation of MHC-I
through the highly conserved serine encoded by exon 7 of the MHC-I cytoplasmic tail.
These studies suggest that the mechanism behind MAPK regulation of MHC-I is through
serine phosphorylation and inhibition of this process allows for a longer surface half-life of
MHC-I molecules leading to better CTL responses. Ultimately, we have shed light on MHCI surface expression, trafficking, internalization and antigen presentation in melanoma.
Knowledge gained through this study could aid in the development of cancer treatment
strategies whereby MAPK pathway inhibition is used to augment the effectiveness of CTLbased immunotherapies. Furthermore, these types of therapeutic approaches may be
generalizable to other tumor types that also demonstrate constitutive MAPK pathway
activation.
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CHAPTER I:
INTRODUCTION AND BACKGROUND
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1.1 MELANOMA
Melanoma is a dangerous form of skin cancer that often develops from melanocytes
exposed to UV radiation and the body’s inability to repair the damaged cells. Unrepaired
DNA damage leads to mutations within the melanocytes that can transform the cells into
cancerous cells. Melanoma is known to metastasize to other parts of the body. Metastatic
melanoma is one of the deadliest and most aggressive forms of cancer, with a 3-year
survival rate of less than 15% [1]. Immunotherapeutic approaches that utilize cytotoxic T
lymphocytes (CTLs) have proven to be very effective at inducing regressions of large, bulky
tumors, and in improving melanoma patient survival [2].
Proto-oncogenes are genes that are known to a have high potential to induce cancer.
The most relevant proto-oncogene in metastatic melanoma is BRAF kinase, a component of
the mitogen-activated protein kinase (MAPK) pathway. Constitutive activation of this
pathway by a characteristic BRAF mutation (V600E) contributes to the fatality of metastatic
melanoma by inducing many uncontrolled cellular changes, including cell proliferation and
immune suppression. Current oncogene- targeted approaches have helped to extend the life
of many patients, but they have generally not proven to be effective in extending the lives of
patients beyond 6 or 7 months. With a better understanding of how the MAPK pathway is
affecting the immune response, we can develop strategies to improve the efficacy of current
melanoma therapies.
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1.2 MAP KINASE SIGNALING PATHWAY
Protein kinases are enzymes that phosphorylate proteins by covalently attaching
phosphate groups to the side chain of serine/threonine or tyrosine residues [3], and regulate
the activity, localization, and function of proteins involved in many cellular processes.
Kinases most commonly are involved in signal transduction and cell cycle regulation. There
are many of distinct protein kinases, and in recent years over 100 different kinases have
been discovered [4]. Based on their substrate specificity, kinases fall within certain family
groupings. Kinases can be characterized as serine/threonine or tyrosine kinases.
This study specifically focuses on serine/threonine kinases, which play a major role
in the control of the cell cycle and in receptor-mediated signaling pathways [5]. Mitogenactivated protein kinases (MAPK) are a group of highly conserved serine/threonine protein
kinases, whose function and regulation have been conserved throughout evolution, from
simple organisms like brewer’s yeast to highly complex organisms, such as mammals [3].
Years of research have been invested to characterize the protein kinases involved in this
pathway. Despite the extensive characterization of the signaling cascade, there are still many
unknowns surrounding the downstream effects of this pathway on gene expression. Because
this signaling pathway is often deregulated in tumor cells, a more complete understanding of
this signaling pathway could lead to improvements of targeted-therapies for cancer patients.
The MAPK pathway specifically consists of the Ras/Raf/MEK/ERK (extracellularsignal-regulated kinase) pathway, a series of protein kinases that regulate the expression of
proteins involved in cellular growth and survival (Figure 1.1) [6,7]. The MAPK pathway
responds to the binding of cytokines, growth factors, hormones, and other stimulating
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factors that bind to receptors on the cell surface [6,7,8]. Because of their important roles in
cellular functions , MAPK components have been studied extensively in human diseases.
MAPKs are responsible for catalyzing the addition and removal of phosphates to
substrate proteins; as such, they act as an on and off switch to control the activity of other
proteins [3]. The process of phosphorylation is regulated by the feedback loop system of
MAPKs and protein phosphatases working in a reciprocal matter to change the behavior of
cells in response to extracellular signals. There are three central, sequentially-activated
kinases that make up the signaling cascade in the MAPK pathway, these three kinases are
known as MAPKKKs (ex. BRAF), MAPK kinase (ex. MEK 1/2), and MAPK (ex. ERK
1/2). These kinases are all serine/threonine kinases that are activated through
phosphorylation and their interaction with GTP proteins of the Ras/Rho family in response
to extracellular stimuli [5,9].
Our study will focus on the ERK 1/2 pathway, one of major MAPK signaling
pathways [10]. The ERK 1/2 pathway was the first pathway identified and currently the best
described MAPK pathway [10]. The ERK cascade typically responds to extracellular growth
signals. In response to stimuli, the Ras-guanosine diphosphate (GDP) is exchanged with
Ras-guanosine triphosphate (GTP) which binds to Raf, leading to the activation of kinases in
the pathway. The binding of RasGTP to Raf family members relays a signal to the MAPK
signal cascade; once the MAPKs are activated, they phosphorylate serine/threonine residues
on their target proteins [10].
There are three Raf proteins expressed by human cells: RAF-1, ARAF, and BRAF
[7]. The focus of this study is the raf protein BRAF. When BRAF is activated, it
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phosphorylates the kinases MEK 1/2, which in turn activates downstream phosphorylation
in the MAPK pathway. In normal cells, the activation of the MAPK pathway is quickly
reversed and the MAPK phosphorylation cascade is switched off [11]. One of the major
hallmarks of cancer is the ability of cancer cells to sustain their proliferation signals.
Mutations that induce the constitutive activation of MAPK pathway components can induce
uncontrolled cellular proliferation, which will be further outlined in the following section.

5

Figure 1.1 Schematic representation of the MAP kinase pathway. MAP kinase
pathway schematic representation showing sequential kinase phosphorylation and
activation. [12] C. Fremin, S. Meloche, From basic research to clinical development
of MEK1/2 inhibitors for cancer therapy, J Hematol Oncol 3 (2010) 8. (Reprinted
with permission of the authors).
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1.3 MAP KINASE PATHWAY SIGNALING BY ONCOGENES
Proto-oncogenes are genes that are activated by changes in normal DNA such as
mutations, translocations, or gene amplifications resulting in increased function for that
individual gene [13,14]. These genetic events lead to its constitutive activation and
dominance over the normal functioning gene. The pathogenesis of malignant tumors can be
largely attributed to the constitutive activation of oncogenes within the tumor cell.
Activating point mutations can lead to the uncontrolled cell proliferation, as described for
the RAS and RAF oncogenes [15,16]. RAS and RAF are components of the MAPK kinase
signaling cascade, and mutations to these proteins RAS or RAF have been identified in
multiple forms cancer with varying degrees of prevalence. Such mutations have been
identified in melanomas, colorectal cancers, lung cancers, sarcomas, liver, and breast
cancers [11].
In melanoma, the MAPK pathway predominantly activating contains mutations in
the NRAS and BRAF proto-oncogenes. NRAS mutations account for 15-20% and BRAF
mutations account for 40-50% of cases of constitutive activation of this pathway [11,13,17].
Over 90% of BRAF mutations consists of a single substitution of thymine with adenine at
nucleotide 1799; this change leads to valine (V) being substituted by glutamate (E) at codon
600, and the mutation is referred to as BRAFV600E [18]. Immunosuppression has recently
been linked to the activation of the MAPK signaling pathway thru BRAF (V600E) mutations.
For example, the oncogenic MAPK pathway upregulates the inflammatory cytokines IL-1
α/β in melanoma cells [19]. Tumor-associated fibroblasts (TAFs) in turn respond to IL-1
upregulation by producing PD-1 ligands, and COX-2, leading to an ongoing suppression of
CTLs preventing them from performing their function [20]. In addition to the suppression of
7

the immune response, BRAF mutations are also associated with a poorer prognosis for these
patients.
The bridge between CTL-mediated immunotherapy and other therapies that target
the BRAF (V600E) mutation has grown tremendously, with a wide array of new developments
in many areas, including combination therapies. As discussed below, there is growing
evidence that such combinations may act in synergy to improve response rates for melanoma
patients.
1.4 BRAF-TARGETED THERAPY AND CLINICAL RESULTS
Each year in the U.S., 76,000 new cases of melanoma are diagnosed, and 9000
people died from the disease in 2012 [21]. The aggressive nature of melanoma, once it
spreads, has been a major issue for the treatment of patients. Early diagnosed cases of
melanoma can be surgically removed, but not all tumors are resectable. In advanced stages
of melanoma, chemotherapy is not very effective due to the rapid development of resistance.
Furthermore, metastatic melanoma proliferates at a rapid pace and can disseminate to almost
any part of the body [21]. Prognosis for metastatic melanoma patients is poor, with only
10% of patients living to 5 years post diagnosis, and the median survival being less than a
year [22].
Many different therapeutic approaches have been taken to treat metastatic melanoma
patients. The FDA-approved chemotherapy for melanoma treatment Dacarbazine induces
objective responses in only 10-15% of patients, but has no benefits for on progression-free
or overall survival of patients. The use of drugs that activate CTLs, like interleukin-2, yield
higher rates of complete responses, but do not result in a higher overall survival rate [23]. In
8

recent years, the focus has turned to the use of oncogene-targeted therapies to provide a
more effective treatment for melanoma sufferers. BRAF-targeted inhibitors have become the
new standard of treatment for aggressive melanomas, but issues with tumor resistance have
plagued clinicians and researchers since the development of these drugs. The need to gain
more knowledge, and better understand how resistance in the MAP kinase pathway drives
tumor progression remains paramount to the development of better treatments for
melanoma.
Dozens of small-molecule inhibitors have been developed over the past couple of
decades to target specific mutated oncogenic proteins within the MAP-kinase pathway
(Table 1.1) and clinical trials have been designed to test these inhibitors. In 2002, the first
BRAF mutations were reported. At that time, Sorafenib was the best available kinase
inhibitor. Sorafenib can inhibit a broad spectrum of cellular targets, such as VEGFR-2,
PDGFR, and C-KIT, FLT-3, CRAF, wild-type BRAF or BRAFV600E [24]. Sorafenib was
able to inhibit BRAF but in order to work for MEK and ERK deactivation, high micromolar
concentrations were required that led to off-target effects and toxicities [25]. Therefore, a
need for more selective oncogene-targeted inhibitors led to the development of BRAF
inhibitors that specifically target mutated BRAF (V600E).
BRAF (V600E) -targeted therapy is one of the most significant therapeutic advances
for the treatment for melanoma in many years. PLX-4032 (Vemurafenib) was the first
BRAF inhibitor approved by the US Food and Drug Administration (FDA) for treatment of
patients with metastatic melanoma or unresectable tumors [26]. GSK2118436 (Dabrafenib)
is another BRAF inhibitor that also has been approved by the FDA. Because both inhibitors
are specific for the mutated BRAF, they are classified as type I BRAF kinase inhibitors
9

[21]. Although both inhibitors can act on WT BRAF at higher concentrations, they have
both induced significant beneficial effects on patients in clinical trials thus far [25].
The first human trials using vemurafenib and dabrafenib were performed in
metastatic melanoma patients [27]. In the vemurafenib phase I clinical trial, 32 patients
enrolled and 81% of the enrolled patients possessed a BRAF (V00E) mutation. Each patient
received the maximum dosage of 960mg twice a day, and both complete and partial
responses were recorded [28]. Phase II and phase III trials confirmed the results from the
phase I trial, and showed about 48% of the patients responded to treatment [29]. Similar
response rates were observed in a parallel dabrafenib phase I trial. In the first dabrafenib
trial, patient tumors were measured at baseline and two weeks after the start of BRAF
inhibitor treatment. The level of ERK phosphorylation was also analyzed at each point. In
patients that responded, 80% showed phospho-ERK inhibition and some patients had
inhibition levels as high as 90-95% [25]. Patient response rates varied from 2 months up to
over 2 years of progression-free survival, but the median duration of response was roughly 7
months.
By contrast, the MEK inhibitor GSK1120212 (Trametinib) is an example of a
selective small-molecule MEK 1/2 inhibitor [22]. In a phase III trial, a total of 322 patients
with metastatic melanoma were randomly treated with either trametinib or one of two
chemotherapy drugs. The overall goal of the trial was to get all patients to progression-free
survival; if this did not occur for patients treated with chemotherapy, they had the option to
switch to trametinib treatment. The median progression-free survival of trametinib-treated
patients was 4.8 months and for the chemo-treated patients it was 1.5 months. At 6 months,
the overall survival was 81% for trametinib patients and 67% in the chemo treated group. At
10

the end of the trial, 22% of patients in the trametinib-treated group had objective responses
compared to only 8% of the chemotherapy treated group [22 ,25].
With all three MAP kinase inhibitors, toxicity and side effects can be a threat to
progression-free survival. Both vemurafenib and dabrafenib caused rashes and the
development of squamous-cell carcinomas in some patients that was attributed to the
appearance of HRAS mutations [30]. The carcinoma lesions that appeared in some patients
were largely managed by excision [30,31]. As for patients treated with trametinib, the side
effects experienced were more severe, ranging from rashes to diarrhea, and peripheral
edema [32] [33].
Table 1.1 Small Molecule Inhibitors Used for Targeting MAPK Pathway.

BRAF-targeted therapy has provided many patients with increased progression freesurvival time, but the development of resistance has been a major problem associated with
treatment. The MAP kinase pathway can contain multiple mutations that activate ERK, and
11

some patients develop alternative mutations (i.e. NRAS) that are not specifically targeted by
BRAF inhibitors. In clinical trials, it was determined that at least two-thirds of patients
developed restored ERK phosphorylation despite prior inhibition [25]. The activation of
ERK signaling took place as early as two weeks into treatment, and in some cases the
amount of ERK phosphorylation was increased in comparison to baseline levels of phoshoERK [25]. Resistance mechanisms include NRAS mutations, alternatively-spliced BRAF
variants, amplification of BRAF and downstream changes to MEK activation [34].
To combat resistance, new potential targets for the MAP kinase pathway have been
identified. Different MEK inhibitors could possibly decrease or prevent the occurrence of
pERK re-emergence post BRAF inhibitor treatment. MEK targets that are downstream of
RAF may be good potential targets. In addition the Phosphatidylinositol-4,5-bisphosphate 3kinase (PI3K), Protein kinase B (AKT), mechanistic target of rapamycin (mTOR) (better
known as the PI3K/AKT/mTOR) pathway is involved in melanoma signal transduction;
phosphatase and tension homolog (PTEN), a suppressor gene in the pathway, suggest
potential additional targets to stop the reactivation of downstream ERK. Pre-clinical data
support the possibility that these pathways are relevant to the pathogenesis of BRAF-mutant
melanoma and could possibly be used by tumor cells as a means for immune evasion [35]
[36].
An alternative approach to treating resistance in metastatic melanoma patients is the
use of combination therapy. For example, in addition to combining targeted agents like
BRAFi and MEKi, more recently the combination of targeted agents with checkpoint
inhibitors, such as ipilimumab, a monoclonal antibody that blocks the co-inhibitory
molecule cytotoxic t-lymphocyte associated protein 4 (CTLA-4), has gained more traction
12

clinically [37]. Ipilimumuab was approved by the FDA in 2011 and is currently undergoing
clinical trials for use in combination with immunotherapies for melanoma patients. In
addition to the use of ipilimumuab, newly developed monoclonal antibodies that block
programmed cell death 1 (PD-1) and its ligand, CD274 (PD-L1) are also being tested
currently. As always, many questions arise as to how these combinations will affect patient
tumor progression, survival and overall health. Regardless, the future of BRAF-targeted
therapy and immunotherapy as means of treatment for metastatic melanoma patients looks
promising, as outlined further below.
1.5 CTL-MEDIATED IMMUNOTHERAPY
Cancer immunotherapies have grown exponentially in recent years; where
chemotherapies have failed, they have proven to be a respectable alternative treatment. The
adaptive immune response relies heavily on immune effector cells known as cytotoxic tlymphocytes (CTLs). Also referred to as CD8+ T-cells, CTLs are known to be major players
in the regression of tumors. CD8+ T-cells recognize major histocompatibility complex class
I (MHC-I) molecules that display peptide antigens on all cell types in the body. In addition
to distinguishing self-antigens and non-self-antigens, effector CD8+ cells can be primed to
target antigens that are located on different types of cancers, known as tumor associated
antigens (TAAs) [38]. Lymphocytes that infiltrate into the stroma of cancer nodules are
referred to as Tumor infiltrating lymphocytes (TILs) [39,40]. TILs provided the first
evidence that the immune system can recognize tumor antigens [41,42]. In 1988, Wolfel et
al. showed that target structures located on human leukocyte antigens (HLA) displayed on
tumor cells could induce the killing of these cells by CTLs [42]. The target structures
identified were later described as the first tumor antigens recognized by T-cells [43].
13

Intracellular proteins are comprised of poly-peptide chains, and within a cell they are split
into shorter peptides that can be presented at the cell surface when loaded onto MHC-I
molecules. Peptides can range from 8 to 12 amino-acids that are derived from specific cellassociated proteins, and are recognized by the T-cell receptor of CTLs [44]. Peptides can
only bind to specific MHC alleles that possess particular amino acid binding motif
preferences [44,45]. The targeting of TAAs through various treatment methods has been the
foundation of cancer immunotherapy.
Several different T-cell based immunotherapies have been developed to treat
melanoma. For example, the cytokine interleukin-2 (IL-2) is responsible for the growth,
proliferation, and differentiation of T-cells to become effector cells. IL-2 is produced by Tcells following T-cell recognition of a foreign pathogen or a tumor antigen. IL-2 as
monotherapy or combinations of IL-2 and TILs were some of the first successful T-cell
mediated immunotherapies developed for the treatment of cancers [39]. Cancer vaccines can
also be used to prime anti-tumor T-cell responses. Melanoma researchers have identified
proteins that are expressed with high frequency amongst most melanoma patients, MelanA/MART-1 and gp-100. Because these proteins are expressed only in melanocytes and
melanoma cells, they are considered good TAA candidates [44,46]. Certain cancer vaccines
utilize peptides derived from these proteins to induce an adaptive immune response. Tumor
antigens combined with an adjuvant can be used to prime the immune system to develop
more antigen specific T-cells and more potent anti-tumor immunity. However, the use of
vaccines for activating T-cells is not without complications, under certain circumstances
peptide-specific T-cells can become tolerized and become unresponsive [47]. This can range
from issues with the dose of peptide or the adjuvant used during immunization. An over14

stimulation of the immune response can also lead to exhaustion of memory T-cells within
the body.
An alternative to peptide vaccines involves using them in conjunction with
professional antigen presenting cells (APCs) that have been loaded with peptides and
injected into patients. The most potent APCs for inducing T-cell activation are dendritic
cells (DCs); T-cell receptors interact with MHC-I on DCs, leading to T-cell priming. DCs
normally internalize protein antigens from cells, process the antigens and then travel to the
lymph nodes to present the peptides to T-cells [48]. APCs also have the unique ability to
present both endogenously derived peptides through MHC-I and exogenously derived
peptides on MHC-II complexes. In a process known as cross presentation, APCs can present
also exogenously-derived peptides on recycled MHC-I molecules [49]. The discovery that
DCs normally uptake antigens and present them to activate T-cell responses led to the
rationale that peptide-loaded DCs would be good candidates for initiating an anti-tumor
response [49,50,51]. Although most DC-based cancer vaccines have shown promise for
inducing anti-tumor T-cells in peripheral blood, induction of clinical responses has been
comparatively rare.
1.6 ROLE OF MHC-I IN T-CELL MEDIATED IMMUNE RESPONSES
MHC-I is a central focus of immune response. Peptides derived from many types of
cells including self, non-self, pathogen, and tumor-derived are displayed by these molecules
to effector T-cells by all nucleated cells of the body. MHC-I molecules are able to present
endogenously-derived peptides, but in professional antigen presenting cells (APCs), such as
dendritic cells (DCs), MHC-I molecules are also able to present exogenously-derived
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peptides. Mature MHC-I complexes are assembled in the endoplasmic reticulum (ER); they
are heterodimers assembled from a polymorphic heavy chain, and a light chain called β2microglobulin (β2m) and antigenic peptide [52,53]. Since they display these peptides at the
cell surface, and MHC-I molecules play an important role in antigen presentation.
Proteasomes degrade cytoplasmic proteins into smaller peptides, which are transported into
the ER by the transporter associated with antigen presentation (TAP) and are loaded in to the
peptide binding grooves of the MHC-I molecules. The MHC-I binding groove
accommodates peptides 8 to 12 amino acids in length [52]. In the ER, MHC-I molecules are
stabilized by chaperone proteins such as calreticulin [54]; in addition, the molecule Tapasin
interacts with TAP to assist in the delivery of peptides to MHC-I molecules. When a peptide
is successfully bound to MHC-I and β2- microglobulin as a trimolecular complex, it exits
the ER via the secretory pathway and travels to the cell surface in vesicles for presentation.
Human MHC-I molecules are referred to as human leukocyte antigens (HLA). The
three classical MHC-I genes are HLA-A, HLA-B, and HLA-C, and each HLA type can
recognize and bind uniquely to certain peptides because of the molecular properties of the
their peptide binding grooves [55]. HLA-A and HLA-B are expressed in higher levels in the
human cells than HLA-C. The extremely high level of MHC-I Polymorphism results in
different peptide-binding grooves that recognize and bind characteristic peptide sequences,
allowing for each individual to present a wide and distinct array of peptides.
Each HLA molecule loaded with peptide is expressed on the cell surface to present
peptides to CD8+ T-cells, this can induce clonal expansion of effector of T-cells, target cell
killing or cytokine release, depending on the APC and T-cell differentiation state. T-cells
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contain a T-cell receptor that binds to MHC-I; when this occurs; many more stabilizing
receptors bind to one another from each cell thus allowing the T-cell to stay in close contact
to release effector molecules. Granzyme B and perforin are two common molecules released
by CD8+ cytotoxic T-cells to induce target cell death. Granzyme B is a serine protease
secreted by T-cells (and other non-cytotoxic cells like mast cells and basophils) that is
involved in inducing inflammatory cytokine release [56]. Perforin is a pore-forming protein
that enters target cells; once inside, it triggers an increase of intracellular calcium and
eventually leads to the apoptosis of target cells [54].
MHC-I molecules possess both an extracellular region that contains the peptidebinding region, a transmembrane domain, and a cytoplasmic tail. The MHC-I cytoplasmic
tail plays a role in antigen presentation, but it has not been extensively studied. Studies have
shown that the tail is involved in intracellular trafficking and antigen-presentation in APCs,
but little is known about its role in tumor cells. The MHC-I cytoplasmic tail is 35 amino
acids in length and is encoded by three exons: 6, 7, and 8. This region is highly conserved
throughout species [52] [57]; Exon 6 and 7 each contain potential tyrosine and serine
phosphorylation sites, respectively [53]. Recent research has revealed that a natural splice
variant occurs in some organisms (not in human beings); whereby exon 7-encoding amino
acids are deleted from cytoplasmic tail region. Previously published work from our lab
revealed that DCs transduced with this exon 7-deleted variant had a longer cell surface halflife and this contributed to better recognition and killing by T-cells [57].
Furthermore, previous studies showed that tyrosine-320 encoded by exon 6 is crucial
for MHC-I endolysosomal trafficking in DCs and contributes to the ability of MHC-I to
acquire and present exogenously derived peptides [53]. MHC-I molecules utilized by DCs
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are extremely important for activating T-cell mediated adaptive immune responses. The fact
that the MHC-I cytoplasmic tail plays a role in trafficking in DCs may also help shed light
on the role of the cytoplasmic tail in antigen presentation by tumor cells or other nucleated
cells, which will be discussed further below.
1.7 MODULATION OF MHC-I BY PATHOGENS AND ONCOGENES
Since MHC-I displays fragments of intracellular proteins on the cell surface, it is
essential for immune surveillance by T-cells. The MHC-I molecule is expressed by all
nucleated cells; any cell can be infected by a viral pathogen, or subjected to mutations that
may lead to cancer. Peptides derived from mutated proteins are presented to CD8+ T-cells,
which in turn can induce an adaptive immune response. Interestingly, pathogens and cancer
cells evolve ways to avoid being detected by the immune system in order to downgrade the
immune response as much as possible. Since MHC-I molecules are so fundamental to the
immune response, they are often the targets of these mechanisms of immune evasion.
Defects in MHC-I mediated antigen presentation renders cells unrecognizable to T-cells and
provide an important advantage to both pathogens and tumor cells.
Several different components of the antigen presentation machinery (APM) can be
lost or targeted, which can have implications for MHC-I mediated antigen processing,
loading, and presentation. For example, defects in the proteasome that cleaves proteins into
peptides have been identified in some tumor cell types. In addition, downregulation of
subunits of the proteasome such as β, ΜΒ1, and Z have been characterized in carcinomas,
colorectal, ovarian and bladder cancers [58,59,60]. In melanoma cells, downregulation of
other inducible subunits (LMP2, 7, and 10) related to the proteasome have been
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characterized [61,62]. Without proteasomes, cells can’t produce the peptides required for
MHC-I surface expression and T-cell killing of target cells. Other APM components
commonly lost in tumor cells are the TAP1 and TAP2 genes. Tumor cells have been found
to downregulate these peptide transporters, which are important for loading peptides onto
MHC-I molecules [58]. In addition, viruses such as HCMV can express proteins that directly
inhibit TAP 1 and 2.
The MHC-I cytoplasmic tail is also a target of viruses within tumor cells. Human
immunodeficiency virus (HIV) is one of the most deadly diseases that can affect humans,
partially due to its ability to escape the immune system. HIV encodes a molecule called Nef,
which targets the MHC-I molecule at the cytoplasmic tail, thus disrupting the trafficking and
intracellular localization of MHC-I [63]. Nef was shown to associate with the cytoplasmic
tail in humans, in a manner that was dependent on the tyrosine-320 residue encoded by exon
6 [63]. When the cytoplasmic tyrosine of the HLA-A2 molecule was mutated, Nef lost the
ability to downregulate the surface expression of MHC-I [64].
Sometimes tumor cells can overexpress growth factor receptors, leading to the
downregulation of MHC-I molecules as a mechanism of immune system escape. For
example, expression of HER2 in breast cancer cells has been shown to inversely correlate
with MHC-I expression. HER2 is a proto-oncogene and a member of the epidermal growth
factor (EGFR) family of tyrosine kinases. A study conducted by Inoue et al. showed that the
overexpression of HER2 led to a downregulation in HLA-A2 molecules and less
recognition by HER2-specific CTLs [65]. Interestingly, mutated HER2 overexpression is
also linked to activation of the MAPK pathway [66].
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Other oncogenic mutations have been shown to regulate the level of MHC-I on the
cell surface. In particular, BRAF inhibitors (BRAFi) have been shown to induce an
upregulation of MHC-I, melanoma differentiation antigens, and other immune system
activators [19]. When metastatic melanoma cells were treated with BRAFi PLX 4720
(vemurafenib) in conjunction with IFN-γ, nanomolar concentrations of vemurafenib
enhanced MHC-I, MHC-II, and β2- microglobulin in Mel A375 cells after 24 hours [67].
This upregulation of MHC- I has also been seen in other melanoma studies. For example,
MAP kinase pathway inhibition induced upregulation of MHC-I and melanoma antigens,
MART-1, gp100, and trp-1/2 in multiple melanoma cell lines after 72 hours of drug
treatment [68].
Notably, BRAF inhibition has been shown in several studies to relieve immune
suppression within the melanoma tumor microenvironment, leading to better CTL
infiltration and function. In vitro experiments have shown that BRAF inhibition can
decrease the release of immunosuppressive cytokines such as, IL-1, IL-6 and IL-8 [19]. In
vivo mouse studies have also shown that PLX4720 (BRAFi) can significantly increase
tumor infiltration of adoptively transferred T-cells, and induce better antitumor activity
through the inhibition of melanoma tumor cell production of vascular endothelial growth
factor (VEGF) [69]. In addition, melanoma patient tissue samples examined after BRAFi
treatment showed an increase in CD8+ T-cell infiltration and markers of T-cell cytotoxicity.
This increase of CD8+ cells was attributed to a decrease in the immunosuppressive
cytokines IL-6 and IL-8 [70].
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An increase in antigen presentation following MAP kinase pathway inhibition
appears to be one outcome of BRAF inhibitor treatment, but it remains unclear how MHC-I
expression is modulated by the MAP kinase pathway at the mechanistic level. This is
important, since MHC-I upregulation following treatment by MAPK inhibitors should lead
to better CTL recognition and killing of melanoma cells. How exactly is the MAP kinase
pathway connected to MHC-I surface expression? A better understanding of how MAPK
pathway and MHC-I are all connected may help shed light on a potentially important
immune system evasion mechanism that tumor cells use. The rationale behind this project is
that MHC-I down regulation on the cell surface of melanoma cells, can be reversed by
treatment with MAPK pathway inhibitors. This occurrence has been documented in
melanoma [65,67,71]. Increases in MHC-I surface expression following inhibitor treatment
suggest that the upregulation is regulated by MAPK signaling. Since the MAPK pathway
induces a phosphorylation cascade, we explored the hypothesis that MHC-I cytoplasmic tail
phosphorylation mediates this connection. A potential model for how this connection might
be mediated is shown in Figure 1.3.
1.8 AIMS OF PROJECT
It is our central hypothesis that MAP kinase pathway activation upregulates MHC-I
surface expression through altering phosphorylation of the MHC-I cytoplasmic tail. The
goal of this project is to identify the mechanism behind the regulation of MHC-I surface
expression, which has yet to be identified in tumor cells [67].
To determine the connection between the oncogenic MAPK pathway and the surface
expression of MHC-I, we explored two aims:
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AIM 1: Assess the effects of MAPK pathway inhibitors on MHC-I surface expression in
melanoma cells and their subsequent recognition by melanoma antigen specific T-cells.
•

Aim 1.1. Determine the effects of three different clinically used BRAF / MEK
inhibitors on total MHC-I cell surface expression with a panel of human melanoma
cells.

•

Aim 1.2 Determine the role of the MHC-I cytoplasmic tail in the MAP kinase
pathway dependent modulation of MHC-I surface expression in melanoma cells.

•

Aim 1.3. Determine if modulating the level of melanoma cell MHC-I surface
expression through MAPK pathway inhibition improves CTL-mediated recognition
and killing.

AIM 2: Identify the mechanism of modulation of MHC-I molecules by the oncogenic
MAPK pathway.
•

Aim 2.1 Determine the steady state rate of internalization of MHC-I molecules in
BRAF mutant melanoma cell lines.

•

Aim 2.2: Determine whether MAPK pathway inhibitors slow the rate of
internalization of MHC-I molecules, and if the process is cytoplasmic tail dependent.

This research is significant because MHC-I molecules are crucial targets recognized by
CTLs to kill tumor cells; thus, strategies to improve MHC-I mediated antigen presentation to
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CTLs are likely to increase the efficacy of current immunotherapies. Knowledge gained
from these experiments can ultimately improve our understanding of how the MAPK
pathway controls MHC-I surface expression, trafficking, internalization, and antigen
presentation in melanoma. A better understanding of how oncogenic signaling pathways
regulate MHC-I may allow for the development of novel cancer treatment strategies
whereby different inhibitors targeting MHC-I downregulation can be used to augment the
effectiveness of CTL-based immunotherapies. Furthermore, these types of therapeutic
approaches may be generalizable to the many tumor types that demonstrate constitutive
MAPK pathway activation.
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Melanoma Cell Containing a BRAF

(V600E)

Mutation
MHC-I

Figure 1.3. Potential role of MHC-I tail phosphorylation in controlling MHC-I trafficking in
melanoma cells. Working model of possible mechanism of the MHC-I cytoplasmic phosphorylation
before and after BRAF inhibition in melanoma cells.
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CHAPTER II:
MATERIALS AND METHODS
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2.1 Cell Culture and Transduction
Human melanoma cell lines expressing BRAFV600E mutations, Mel888 and WM793
were transduced with HLA-A*0201 isoforms using lentiviral gene transfer vectors (Figure
3.2 A). The human (hPGK) promoter was used to drive the expression of WT, ∆T, ∆S and
∆Y HLA-A*0201 isoforms [57]. Transduced cells expressing similar levels of surface HLAA2 were isolated by cell sorting (Figure 3.2 B). Additionally, three untransduced human
melanoma lines were utilized, two BRAF-WT cells HS294T, Mewo and Melanocytes.
Mel888 lines were cultured in RPMI 1640 medium (GIBCO Grand Island, NY) containing
10% fetal bovine serum (GIBCO), 10 IU/mL penicillin (Cellgrow Manassas, VA), 10
µg/mL streptomycin (Cellgrow), Insulin-Transferrin-Seleum-A (GIBCO) and maintained at
37°C in 5% CO2. WM793, HS29T, and MeWo cells were grown in similar media without
the addition of insulin. Melanocytes were cultured in HEMa media (Life Technologies).
TILs were utilized in T-cell assay experiments. TIL were maintained in RPMI-1640 medium
containing 10% fetal bovine serum, 10 IU/mL penicillin, 10ug/mL streptomycin and
supplemented with 200 IU/mL of IL-2.

2.2 Isolation and REP of TIL

MART-1 CD8+ specific tumor infiltrating lymphocytes (TIL) obtained from infusion
product (>98% MART-1 specific) were generously donated by Dr. Laszlo Radvanyi (M.D.
Anderson Cancer Center Houston, TX). To obtain TILs, melanoma tumor cells were
resected from stage IV- melanoma patients. The tumors were cut into 3-5mm2 fragments.
The fragments were placed in a 24 well plate with TIL culture media (TIL-CM) and 6000
IU/ml interleukin-2 (IL-2) to grow TIL from the fragments. After 3 weeks in TIL-CM the
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Pre-Rapid Expansion (pre-REP) TILs were transferred to T-25 flasks for rapid expansion.
The REP was performed in upright T-25 flasks by activating 1.3 X 105 pre-REP TIL with 26
X 106 allogenic, irradiated (5000cGy) PBMC feeder cells with 30ng/ml OKT3 (anti-CD3;
Abbott Park, IL) in 1:1 mixture of TIL-CM and AIM -V (Invitorgen). TILs expanded from
tumor fragments were harvested after 5 weeks and stained for CD8 expression and
recognition of the HLA-A2 MART-1 peptide tetramer. TILs were designated as pre-REP
and were re-stimulated with MART-1 peptide. The TILs were expanded for another 12 days
and diluted as needed with AIM -V and IL-2 to keep the viable cell density in the range of
1–2 × 106/ml. The post-REP TILs were isolated and washed in TIL-CM and rested for 3–6
hrs. before re-stimulation. Expanded TILs were routinely stained for human T cell
differentiation markers using fluorochrome-conjugated mAb recognizing CD3, CD4, CD8,
CD27, CD28, CD57, and CD62L obtained from BD Biosciences (San Jose, CA) or
eBiosciences (La Jolla, CA). TILs were stained with HLA-A2 MART-1 peptide
(ELAGIGILTV) tetramer (Beckman Coulter, Fullerton, CA) to track changes in the MART1–specific CD8+ subpopulation. The stained cells were acquired by using a BD FACScanto
II flow cytometry analyzer and FACSDiva software (BD Biosciences). Data were analyzed
by FlowJo software (TreeStar, San Carlos, CA).

2.3 MAPK Pathway Inhibitors
BRAF V600E inhibitor GSK2118436 (Selleckchem), and MEK inhibitors
GSK1120212 (Selleckchem), and AZD6244 (Selleckchem), were used to treat melanoma
cells. Each MAPK pathway inhibitor was titrated for optimal concentration and incubation
time (Figure 3.1B). Inhibitors were dissolved in DMSO and stored at -80 in aliquots.
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2.4 Antibodies and Flow cytometric analyses

Analysis of surface MHC-I expression on melanoma cell lines was carried out by
standard flow cytometry methods. Anti-human HLA-A2-APC (BB7.2) , Anti-human HLA
A,B,C-APC (w6/32), Anti-human IFN-g-PE (B27), Anti-human CD8-Pacific Blue (SK1),
Alexa Flour 647 (IgG2b) Isotype control antibodies were obtained from the following
(Biolegend San Diego, CA); Streptavidin-APC was obtained from (BD Biosciences) and
HLA antibody A1,A36 –Biotin conjugated was obtained from (US biological). Transduced
melanoma cell lines were cultured with BRAF inhibitor or MEK inhibitors and untreated
control (RPMI only) for 3hrs. Cells were seeded at 1.0 X 106 cells in a 12 well plate. Each
inhibitor was diluted in 10mL of growth media to 100nM each and added to each well to a
volume of 2mL and a final concentration of 50nM. After treatment melanoma cells were
washed, and stained either with HLA-A2, HLA-A, B, C, or HLA-A1 molecules
respectively, and analyzed using FACScantoII flow cytometer (BD Biosciences, Jose CA).
For TILs intracellular antigens were stained using the fixation and permeabilization protocol
from the BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit with BD
GolgiPlug™ (BD biosciences San Jose CA). Stained cells were analyzed using a
FACScanto II flow cytometer (BD Biosciences San Jose CA). Data was analyzed using
Flowjo analysis software (Treestar Ashland OR).

2.5 T-cell assays
For all T-cell assays MART-1 CD8+ specific TILs obtained from infusion product
(>98% MART-1 specific) were used. Transduced WM793 cell lines were pulsed with
titrated concentrations of MART-1 peptide, and co-cultured with effector MART-1 TILs at a

28

1:1 ratio (10,000 tumor: 10,000 effector cells) and incubated at 37°C for 4hrs, following a
3hr incubation with BRAF inhibitor (50nM). Transduced Mel888 cell lines were co-cultured
with effector MART-1 TILs at a 1:1 ratio at 37°C for 4hrs, following a 3hr incubation with
BRAF inhibitor. TILs were collected and cytokine IFN-γ production was measured by
intracellular cytokine staining. TIL were incubated with melanoma cell lines for 4hrs in the
presence of GolgiStop (BD Biosciences), washed, fixed, permeabilized, and stained using
anti-mouse or anti-human IFN-γ conjugated to APC (BD Biosciences). The cells were
incubated for 4 hours because GolgiStop is toxic to cells when in culture past 6 hours.
Human T-cells were also stained a fluorescently labeled anti-human CD8 antibody
conjugated to Pacific Blue (BD Biosciences). Antigen-specific intracellular IFN-γ
production by CD8+ T-cells was then determined by flow cytometric analysis.

2.6 Enzyme-linked immunosorbent assay
ELISA’s were performed with WM793 and Mel888 transduced cell lines. Each cell
line was seeded into 20,000 cells per well in 96 well plates. BRAF inhibitor (GSK2118436)
was used to treat cells at concentration of 50nM per well for 3 hrs. Concurrently cells were
also incubated without inhibitor for 3hrs in media as a control. Two hours into treatment
WM793 cells were pulsed with MART-1 peptide for 1 hr., after an hour the cells were
washed with PBS twice and re-suspended in media. After 3 hours of inhibitor treatment
MART-1 specific TILs were added to the media at various tumors to TIL ratios and
incubated overnight. After 8hrs of incubation, the media was collected from each well and
used to determine the amount of IFN-γ secreted from the TIL using the Ready Set GO!
ELISA Human IFN-γ kit (eBiosciences). Plates were read using SpectraMax® M5/M5e
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Multimode Plate Reader and program. Data was analyzed with the Excel spreadsheet
program.

2.7 Western Blotting
BRAF WT cell lines HS294T and Mewo, BRAF mutant melanoma cells, WM793
and Mel888 were incubated for three hours in BRAF and/or MEK inhibitor at 50nM and
100nM concentrations. Cell lysates were prepared and protein content was normalized using
the BCA method (Thermo-Fisher Rockford, IL). Membranes were probed with antibodies
against total MEK, P-MEK, total MAPK, P-MAPK (Cell signaling) and total ERK2 (Santa
Cruz Biotechnology). Protein was analyzed using the Scientific Pierce Fast Western Blot Kit
(Thermo-Fisher Rockford,IL).

2.8 Internalization Assay
Untransduced and HLA-A2 transduced Mel888, WM793 and Mewo cells were
incubated in BRAF inhibitor (GSK2118436) for 3 hrs. in 6 well plates at 1.0 X 106 cells per
well. To determine the effect of the BRAF inhibitor on internalization of MHC-I, drug was
washed off the cells with PBS and the cells were re-suspended in drug-free media. Next,
each plate was placed into 4 degree at different time points 0 minutes (point directly after
drug removal), 30, 60, 90, and 180 minutes respectively to stop internalization. After the
final time point was collected the cells were then washed and stained with HLA-A2 APC
(Biolegend, San Diego, CA) antibody at 1:200 dilutions. Stained cells were analyzed using a
FACScanto II flow cytometer (BD Biosciences San Jose CA). Data was analyzed using
Flowjo analysis software (Treestar Ashland OR).
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2.9 Confocal Microscopy

All cells were seeded and plated in Ibidi 12-well chamber on microscope glass slides
(Ibidi, Verona, WI). For internalization steady state assays all cells were cultured in RMPI
1640 media (GIBCO Grand Island, NY) with 10% FBS (invitogen), 20mM HEPES
(Invitrogen). Mel888 and WM793 cells were placed on ice to stop internalization and
labeled with AF488 antibody (Biolegend) for 30 minutes. The cells were then incubated for
0, 30, 60, and 180 minute time points. The cells were washed twice with PBS, and fixed
with 4% PFA for 10 minutes. At each time point the cells were taken out and fixed, after
each sample was fixed the cells were then stained for surface MHC-I using goat anti mouse
AF555 antibody (Biolegnd) for 30 minutes on ice. After the surface is stained the nucleus is
then labeled with Hoechst for 10 at room temperature, then washed twice. The cells were
then imaged using Leica SP2 confocal microscope with 63X oil lens and 1.4 N/A.

To analyze internalization with or with BRAF inhibitor the cells were first labeled at
14 degrees for 30 minutes with MHC-I antibody AF488 (Biolegend). The cells were washed
twice with PBS. The cells were then treated with either 50nM of dabrafenib diluted in
DMSO (Selleckchem) for 90 minutes or untreated control with only DMSO (invitogen). The
time point 90 minutes was used because the cells become very unhealthy with repeated
washings and treatment at later time points. After 90 minutes the cells were then washed,
and fixed with 4% PFA for 10 minutes, and surface MHC-I was labeled with goat anti
mouse AF555 (Biolegnd) at room temperature for 1 hour. After the surface was stained the
nucleus was then labeled with Hoechst for 10 at room temperature, and the cells were
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washed twice. The cells were then imaged using Leica SP2 confocal microscope with 63X
oil lens and 1.4 N/A.
2.10 Statistical analysis
Graph Pad Prism 6 was used for graphing and statistical analysis. A student’s t- test was
used to analyze the statistical significance of all flow data. A one-way ANOVA test was
used to analyze confocal microscopy quantification data. A p-value less than or equal to
0.05 was the cut-off to determine the significance of the statistics.
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CHAPTER III:
RESULTS
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Overview
MHC-I expression can be upregulated in BRAF mutant melanoma cells following
MAPK pathway inhibition [67]. Our experiments sought to shed light on the mechanism
behind the modulation of MHC-I expression and the specific role that the MHC-I
cytoplasmic tail may play in this phenomenon. It is known that the tyrosine (Y320) encoded
by exon 6 and amino acids encoded by exon 7 of the MHC-I cytoplasmic tail are involved in
MHC-I trafficking [52,53]. Therefore, we hypothesized that phosphorylation of the tyrosine
(Y320) or serine (S355) from exon 7 may be controlled by the oncogenic MAP kinase
signaling pathway, thus affecting MHC-I intracellular trafficking. In order to determine this,
we examined BRAF mutant melanoma cell lines to further understand the modulation of
MHC-I by the oncogenic MAP kinase pathway and to identify a possible mechanism behind
regulation of MHC-I.
3.1 Inhibition of the MAP kinase pathway increases HLA-A, B, C surface expression in
BRAF mutant cell lines.
In previously published reports, the increase in MHC-I expression after MAP kinase
pathway inhibition was observed after 24-72 hours of treatment. However, these late time
points pointed to transcriptional upregulation of MHC-I, which was of concern in our study.
We therefore wanted to focus on earlier time points, less than 3 hours that may uncover
post-transitional modifications as opposed to the effects of transcription factors that can take
place within 24hrs of treatment [72].
To determine an optimal time point for drug treatment to inhibit the MAP kinase
pathway and to induce changes in MHC-I expression we tested the BRAFi at times 0
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minutes, 30 minutes, 60 minutes, and 180 minutes. We then performed flow cytometry
analysis to determine the level of total MHC-I on the cell surface at each time point. The
results in Fig.3.1A show that after 180 minutes of MAPK pathway inhibition, MHC-I is
maximally upregulated on the cell surface in comparison to the untreated control.
To determine the kinetics of blocking the BRAF signaling pathway, we evaluated the
levels of MAPK phosphorylation as readout for MAPK pathway activation. Total ERK was
used as a control for phospho-ERK. The results shown in Fig. 3.1B reveal that the level of
ERK phosphorylation was substantially reduced after 3 hours of treatment using both a
BRAF inhibitor (Dabrafenib) and a MEK inhibitor (Trametinab) for 3 hours at low
concentrations (10nM), or high concentrations (50nM), compared to vehicle (DMSO)
treated cells. In addition, a BRAF WT control cell line, HS294T, showed no change in the
level of phospho-ERK following treatment with the BRAF inhibitor (Dabrafenib. These
results confirmed that the MAPK signaling pathway was blocked at the drug concentrations
and time points tested.
Next we examined the effects of two clinically used MAPK pathway inhibitors,
Dabrafenib, and Trametinab on the surface expression of total MHC-I molecules. We treated
melanoma cells for 3 hours at a 50nM concentration and as a control, we used DMSO only
(vehicle). The levels of MHC-I were observed by flow cytometry and mean fluorescence
intensity (MFI) was measured to determine difference in total MHC-I expression in two
BRAF mutant cells lines (Mel888 and WM793) and one BRAF WT line (HS294T) (Fig.
3.1C). The results show that MHC-I was upregulated in the BRAF mutant cells, while the
level of MHC-I did not change in the BRAF WT line. These results ultimately show that the
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oncogenic MAPK signaling pathway can affect the level of MHC-I surface expression in
melanoma cells and that MAPK inhibition can reverse these effects.
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Figure 3.1 Inhibition of the MAP kinase pathway increases HLA-A, B, C surface
expression in BRAF mutant cell lines. (A) Mel888 and WM793 BRAF mutant cell lines
were treated with DMSO (vehicle) or dabrafenib for 30 minutes and 3 hours later total
surface HLA-A,B,C was stained with W6/32 antibody and cells were analyzed by Flow
cytometry. Values represent the mean florescence intensity (MFI) (B) Cells were treated
with vehicle (DMSO), 10uM, or 50uM of dabrafenib (BRAFi). Mel888 was also treated
with Trametinib (MEKi) (indicated by *). Whole cell lysates were prepared and levels of
phospho-ERK and total ERK were analyzed by immunoblotting. (C) Two BRAF mutant cell
lines, Mel888 and WM793 and one BRAF WT cell line, HS294T were treated with DMSO
(vehicle), dabrafenib(BRAFi) and trametinib (MEKi) for 3 hours. Following treatment the
cells were stained with W6/32 antibody to measure HLA-A, B, C and analyzed by flow
cytometry. Left panels show shifts of MHC-I as histograms, and the right panels show actual
MFI of MHC-I in a bar graph format. These experiments were repeated at least four times to
confirm results. (* indicates p < 0.05; NS: not significant).
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3.2 Creation of cell lines expressing HLA-A2 cytoplasmic tail variants
To determine if the MHC-I cytoplasmic tail was involved in the modulation of
MHC-I by the MAP kinase pathway, cell lines transduced with cytoplasmic tail mutations of
HLA-A2 were made. The melanoma cell lines Mel888 and WM793 were selected for
transduction because they lack the expression of endogenous HLA-A2, and also possess a
targetable BRAF activating mutation (V600E). Lentiviral vectors [57] were used to
transduce the cell lines with WT HLA-A2; ∆T-A2, containing a complete deletion of the
cytoplasmic tail; ∆S, a point mutant that replaces the serine to an alanine at S335, and ∆Y,
containing a similar point substitution to tyrosine(Fig 3.2 A). The transduced cells were then
sorted, and immunoblotting was used to confirm that the correct HLA-A2 tail variant was
present in each cell line (Fig 3.2 B). Surface expression of HLA-A2 was checked by flow
cytometry to ensure that the surface expression comparable was between all cell lines
expressing the HLA-A2 variants (Fig 3.2 C).
Following transduction of the BRAF mutant cells, we next wanted to determine if
the inhibitors were able to successfully block the MAPK signaling pathway in the HLA-A2
transduced cell lines. We evaluated the levels of MEK and ERK2 phosphorylation as
readout for MAPK pathway activation in the WT-A2 and ∆T-A2 lines. Total ERK and MEK
were also used as a control. The results in Fig. 3.2 D reveal that the levels of MAPK
phosphorylation were significantly reduced after 3 hours of treatment with both the BRAF
inhibitor (Dabrafenib) and the MEK inhibitor (Trametinab). The cells were treated with a
low concentration (10nM), a high concentration (50nM), and a vehicle (DMSO). The results
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also show that 50nM of drug was sufficient to block ERK and MEK phosphorylation within
3 hours.
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Figure 3.2. Creation of cell lines expressing HLA-A2 cytoplasmic tail variants (A and
B) Amino acid sequences of the cytoplasmic domains of WT, ∆T, ∆S, and ∆Y HLAA*0201. Tyrosine 320 and Serine 335 phosphorylation sites are depicted in red. Bottom,
Lentiviral vectors used to transduce BRAF mutant melanoma cells. The human
phosphoglycerate kinase (hPGK) promoter was used to drive the expression of WT, ∆T, ∆S,
and ∆Y isoforms of HLA-A*0201. (C) Mel888 and WM793 melanoma cells were
transduced to express comparable levels of surface HLA-A*0201, as determined by HLAA2-specific western blot and mAb staining and flow cytometry. (D) Cells were treated with
vehicle untreated (DMSO), 10uM, or 50uM of dabrafenib (BRAFi) and trametinib (MEKi).
Whole cell lysates were prepared and levels of phospho-MAPK and ERK were analyzed by
immunoblotting.
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3.3 The MAPK pathway regulates the surface expression of MHC-I in a
cytoplasmic tail-dependent matter.
To determine if the MAP kinase pathway modulation of MHC-I was dependent on
the cytoplasmic tail, we analyzed HLA-A2 WT and ∆T-A2 transduced BRAF mutant cell
lines Mel888 and WM793. Each were treated with DMSO (vehicle), dabrafenib, or
trametinib for 3 hours. Following treatment, the cells were stained with HLA-A2 specific
antibody (BB7.2) and analyzed by flow cytometry to determine the levels of HLA-A2 on the
cell surface following treatment (Fig. 3.3A). The results revealed that there was an
upregulation in the HLA-A2 transduced WT cell line, while the tailless cell line showed no
change in MHC-I surface expression. Therefore, indicating that the MHC-I cytoplasmic tail
must be involved the upregulation of MHC-I on the cell surface following BRAF inhibitor
treatment.
In these experiments, we also analyzed HLA-A1 as an endogenous control in all of
our HLA-A2 transduced cell lines. We used HLA-A1 because it has a WT cytoplasmic tail
and should there be subjected to surface expression changes after inhibitor treatment. We
examined the WT and tailless HLA-A2 cell lines; each were treated with 50nM of
dabrafenib or trametinib for 3 hours, and following treatment the cells were stained with an
HLA-A1 specific antibody to observe the surface expression level post treatment of drug. As
expected, the results revealed that HLA-A1 increased in both the WT-A2 and tailless HLAA2 cell lines, similar to the total MHC-I increase shown in Fig. 3.3B.
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Figure 3.3 The MAPK pathway regulates the surface expression of MHC-I in a
cytoplasmic tail dependent matter.
(A) HLA-A2 transduced Mel888 and WM793 cells were treated with DMSO (vehicle),
dabrafenib (BRAFi), or trametinib (MEKi) for 3 hours. Following treatment, the cells were
stained with HLA-A2 antibody (BB7.2) and analyzed by flow cytometry. Left panels show
MHC-I surface expression as histograms and the right panels show MFI of MHC-I as a bar
graph. (B) HLA-A1 was measured by flow cytometry in Mel888 and WM793 cells
transduced with WT-A2 and ∆T-A2 following treatment with 50uM BRAF or MEK inhibitor
for 3 hours. Left panels show changes of MHC-I surface expression as histograms and the
right panels show MFI of MHC-I in a bar graph format. These experiments were repeated at
least four times with similar results. (* indicates p < 0.05; NS: not significant).
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3.4 Highly conserved serine-335 of the MHC-I cytoplasmic tail mediates modulation of
MHC-I surface expression by the MAPK pathway.
Since our results revealed a connection between the MHC-I cytoplasmic tail and
MAP kinase pathway inhibition, we next wanted to determine which regions of the MHC-I
tail might mediate this connection. To determine which part of the MHC-I cytoplasmic tail
modulated MHC-I expression, we next analyzed HLA-A2 cytoplasmic tail point mutants ∆Y
and ∆S. Point mutants of the tyrosine (320) and Serine (S335) were used because they are
both putative sites of phosphorylation on the cytoplasmic tail. If the tyrosine or serine are
key sites involved in MHC-I modulation, we might be able to see that mutating these sites
will abrogate modulation of surface expression of HLA-A2 in the untreated vs the drugtreated cell lines. To determine if the MAP kinase pathway modulation of MHC-I was
dependent upon the two conserved phosphorylation sites, we assessed ∆Y and ∆S HLA-A2
expression in transduced BRAF mutant cell lines Mel888 and WM793. Each cell line was
treated with DMSO (vehicle), dabrafenib, or trametinib for 3 hours. Following treatment, the
cells were stained with HLA-A2 specific antibody (BB7.2) and analyzed by flow cytometry
to determine the levels of HLA-A2 on the cell surface following treatment (Fig. 3.4A).
In a similar manner to the previous experiment, we analyzed at endogenous HLAA1 as a control in the ∆Y and ∆S cell lines. Each was treated with 50nM of dabrafenib and
trametinib for 3 hours; following treatment, the cells were stained with an HLA-A1 specific
antibody to observe the surface expression level post treatment. The results revealed that
HLA-A1 expression increased in both the cell lines similar to the total WT MHC-I as
expected (Fig. 3.4B).
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The results revealed that the ∆Y-A2 molecule behaved in a similar matter to the WTA2 molecule, while ∆S-A2 acted similarly to ∆T-A2. These results suggested that the MHCI cytoplasmic tail modulation is serine-dependent and not tyrosine-dependent. These results
are the first to not only connect the cytoplasmic tail to MAP kinase signaling pathway but
also to implicate a particular conserved phosphorylation site to the surface expression of
MHC-I in tumor cells.
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Figure 3.4 Highly conserved serine-335 of the MHC-I cytoplasmic tail mediates
modulation of MHC-I surface expression by the MAPK pathway.
(A) Two BRAF mutant cell lines, Mel888 and WM793 were transduced to express HLA-A2
with point mutations to Y320 (∆Y-A2) or S335 (∆S-A2). Each cell line was treated with
DMSO (vehicle), dabrafenib, or trametinib for 3 hours. Following treatment, the cells were
stained with BB7.2 HLA-A2 antibody and analyzed by flow cytometry. Left panels show
surface expression of MHC-I depicted as histograms and the right panels show MFI of
MHC-I expression in a bar graph format. (B) HLA-A1 was measured by flow cytometry in
two BRAF mutant cell transduced with ∆Y-A2 or ∆S-A2 following treatment with 50uM
BRAF or MEK inhibitor for 3 hours. Left panels show MHC-I expression as histograms and
the right panels show actual MFI of MHC-I as a bar graph. These experiments were repeated
at least four times with similar results. (* indicates p < 0.05; NS: not significant).
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3.5 BRAF inhibitor treatment of BRAF mutant cell lines increases subsequent T-cell
recognition and IFN-γγ secretion.

To assess the significance of inhibitor-mediated MHC-I upregulation, we next measured
the effect of these changes on T cell recognition and activation. Thus, we sought to
determine the T-cell response to each transduced HLA-A2 cell line following BRAF
treatment. In the first set of experiments, we analyzed CD8+ MART-1 specific TIL (> 90%
tetramer recognition) of Mel888 cells which naturally express MART-1 [73]. WM793 cells
pulsed with MART-1 peptide were used as targets because they do not express MART-1
protein naturally. Mel888 cells transduced with HLA-A2 variants were treated with the
BRAF inhibitor dabrafenib for 3 hours, the cells were washed, and T-cells were added at a
1:1 ratio in triplicate. Golgi block was added to the media to block the secretion of IFNγ and the cells were co-incubated with T-cells for 8 hours. T-cells were collected and
washed, then stained with antibody for CD8+ T-cell markers. T-cells were then
permeabilized, and stained for intracellular IFN-γ. All cells were then observed by flow
cytometry, with appropriate controls used to detect background levels of IFN-γ (Fig 3.5A).
TIL alone with no melanoma cells, as well as melanoma cells done with no TIL were used
as controls. The results revealed that the TIL co-cultured with WT-A2 and ∆Y-A2 HLA-A2
transduced cells produced more IFN-γ after BRAF inhibitor treatment. However, TIL cocultured with ∆T-A2 and ∆S-A2 transduced cell lines showed no significant increases in
IFN-γ secretion consistent with the flow cytometry results. These results show that the
inhibition of oncogenic BRAF can have a direct effect on TIL IFN-γ production.

54

We also repeated the experiment using HLA-A2 transduced WM793 cells, except
the cells were incubated with 50nM of MART-1 peptide for the final hour of the 3 hour
BRAFi treatment. Similar to the results with Mel888 cells, the results from these
experiments correlated well with our MHC-I flow cytometry results. As expected, the Tcells produced more IFN-γ in response to exposure to the cell lines transduced with WT-A2
and ∆Y-A2. By contrast, notable were the results of the ∆T-A2 and ∆S-A2 cell lines, which
elicited only slight decreases or no change in the frequency of IFN-γ positive CD8 cells in
comparison to those cells co-cultured with untreated cells (Fig 3.5B).
In order to understand how cytokine secretion by the MART-1 T-cells related to
antigen presentation, T2 cells were pulsed with increasing concentrations of MART-1
peptide and assessed IFN-γ secretion elicited by T-cells was measured. In parallel, the same
MART-1 specific TILs were incubated with Mel888 cells before and after BRAF inhibitor
treatment. An IFN-γ ELISA was performed with the transduced Mel888 cells after a 3 hour
treatment with BRAFi or with DMSO; each cell line was co-cultured with MART-1 TIL for
8 hours, and we measured the levels of IFN-γ secreted into the supernatant. The results in
Figure 3.5C show the level of IFN-γ released by the TIL incubated with transduced Mel888
cells in comparison to the level of IFN-γ released in response to peptide-pulsed T2 cells.
The top panel shows that the WT-A2 cell line had what would be an equivalent of a 4-fold
increase of peptide on the cell surface, following BRAF treatment in comparison to the T2
peptide-pulsed cells. The ∆Y-A2 cell line displayed what would equate to a 6-fold increase
of peptide on the cell surface when compared to T2 cells pulsed with peptide. These results
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demonstrate how the upregulation of MHC-I surface expression has on the cell surface can
affect T-cell recognition.
We also measured the level of IFN-γ secreted into the supernatant by MART-1
specific TILS co-cultured with WM793 cells pulsed with 50nM of MART-1 peptide. (Fig
3.5D). The results were consistent with our previous experiment: MART-1 TILs co-cultured
with WT-A2 and ∆Y-A2 expressing cells showed increases of IFN-γ; following BRAFi
treatment. By contrast, TILs co-cultured with ∆T-A2 and ∆S-A2 showed no change in IFN-γ
released. These results confirm that the MHC-I upregulation by the MAPK pathway plays a
potentially significant role in immunological recognition of tumor cells by T-cells. Our
results also point to serine-335 as the site that could be the key to this mechanism.
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Figure 3.5 BRAF inhibitor treatment of BRAF mutant cell lines increases subsequent
T-cell recognition and IFN-γγ secretion. (A)Frequency of IFN-γ expressing CD8+ T-cells
following co-culture with MART-1 expressing Mel888 cells transduced to express WT
HLA-A2 or cytoplasmic tail variants of HLA-A2: ∆T, ∆Y, and ∆S. Cells were treated with
BRAF inhibitor for 3 hours, washed, and then co-cultured for 8 hours with MART-1 specific
T-cells. Frequency of IFN-γ positive T-cells are shown for each cell line with or without
inhibitor treatment. (B) Frequency of IFN-γ cytokine-expressing CD8+ T-cells following coculture with WM793 cells pulsed with 50nM of MART-1 peptide. Cells were treated with
BRAF inhibitor for 3 hours including MART-1 peptide for the final hour, washed, and then
co-cultured for 8 hours with T-cells. (C) Results of ELISA assay measuring IFN-γ released
into the supernatant by MART-1 specific T-cells after 8 hour co-culture with HLA-A2
transduced Mel888 cells, treated with or without BRAF inhibitor for 3 hours. In parallel, T2cells pulsed with a titrated amounts of MART-1 peptide were assessed as stimulator cells for
the same CD8+ T-cells.(D) MART-1 peptide pulsed HLA-A2 transduced WM793 cells
treated with BRAF inhibitor or DMSO (vehicle) for 3 hours. All experiments were repeated
at least three times with similar results. (* indicates p < 0.05; NS: not significant).
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3.6 Assessing the steady-state rate of internalization of MHC-I in BRAF WT and
BRAF mutant cell lines.
In order to better understand the mechanism behind the oncogenic regulation of
MHC-I surface expression; we next initiated a series of confocal microscopy experiments.
We first compared the steady state internalization rates of MHC-I in the BRAF mutant cell
line Mel888 and the BRAF WT cell line HS294T. Cells were first seeded and plated onto
Ibidi 12-well chambers on microscope glass slides. Cells were put on ice to stop
internalization, and stained with AF488–labeled with W6/32 antibody to stain for total
MHC-I. Cells were incubated at 37 degrees for various time points, after which they were
taken out, fixed, and surface stained using goat anti mouse antibody conjugated with AF555.
Cells were then observed by confocal microscopy.
The result for the HS294T cells shows that MHC-I surface expression does not
significantly change from baseline to 180 minutes. In addition the level of MHC-I
internalized also remains close to baseline levels after 180 minutes (Fig 3.6A). By contrast,
Mel888 cells showed significant internalization of MHC-I over the same time period (Fig.
3.6B). These results reveal that there is a more rapid constitutive rate of MHC-I
internalization in Mel888 cells compared to HS294T cells. These results are consistent with
our flow cytometry studies (Fig 3.1C) and support the notion that oncogenic BRAF is
driving the enhanced internalization observed.
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Figure 3.6 The steady-state rate of internalization of MHC-I in BRAF WT and BRAF
mutant cell lines. (A) Confocal microscopy analysis of the BRAF WT cell line HS294T.
The red fluorescence represents surface MHC-I, green is total MHC-I, and the bottom panel
shows a merged image (yellow). (B) Quantification of the average pixel fluorescence per
cell of surface MHC-I (red) and internalized MHC-I (green in merged image). (C) Confocal
microscopy analysis of the BRAF mutant cell line Mel888. (D) Quantification of the
average pixel fluorescence per cell of surface MHC-I (yellow in merged image) and
internalized MHC-I (green in merged image). All experiments were repeated twice with
similar results. Imaging done by Dr. Zeming Chen
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3.7 BRAF inhibitor slows constitutive MHC-I internalization in a cytoplasmic tail
dependent matter.
After determining that MHC-I is rapidly internalized in BRAF mutant cell lines, we
next wanted to know if MAP kinase pathway inhibition affected this internalization.
Abrogation of MHC-I internalization may lead to the increase in cell surface MHC-I that we
have consistently observed after BRAFi treatment. If this is the mechanism, we would
expect that following removal of the BRAFi, MHC-I should begin to internalize again and
return to baseline surface levels. To test this prediction, we treated Mel888 cells with BRAF
inhibitor for 3 hours and measured total MHC-I at different time points, following drug
removal. As expected, MHC-I surface expression increased by flow cytometry following
inhibitor BRAF treatment in Mel888 cells but not WT BRAF-expressing MeWo cells (Fig
3.7A). However, following drug removal, MHC-I surface levels in Mel888 cells
progressively decreased until falling back to baseline levels by 3 hours. These results
support a model in which BRAF inhibitor treatment halts or slows MHC-I internalization in
BRAF mutant cells, which leads to an increase in MHC-I on the cell surface. Since the WT
BRAF-expressing cell line, MeWo showed no change in MHC-I following BRAFi treatment
and after removal of drug, this supports the idea that oncogenic BRAF is driving the rapid
and constitutive internalization of MHC-I.
We next wanted to determine how the MHC-I cytoplasmic tail affected MHC-I
internalization in the Mel888 cell line. A similar experiment to the one described above was
performed, except that we monitored HLA-A2 surface expression in Mel888 cells
transduced with WT-A2 and tailless A2. WT HLA-A2 demonstrated similar dynamics of
surface expression changes as total MHC-I in response to BRAFi addition and removal (Fig
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3.7B). However, tailless HLA-A2 showed no change in MHC-I surface expression
following drug addition and removal. These results show that constitutive internalization of
MHC-I in Mel888 is not only dependent upon oncogenic BRAF, but also the MHC-I
cytoplasmic tail.

66

Figure 3.7 BRAF inhibitor slows constitutive MHC-I internalization in BRAF mutant
melanoma cell line. (A) Dynamics of total MHC-I surface expression in Mel888 cells
following addition and removal of the BRAF inhibitor. BRAF-WT expressing MeWo cells
were used as a negative control. Cells were observed by flow cytometry at different time
points, following staining with W6/32 mAb. (B) Dynamics of HLA-A2 surface expression
following addition and removal of BRAF inhibitor in Mel888 cells transduced to express
WT HLA-A2 or tailless HLA-A2. Cells were observed by flow cytometry at different time
points following staining with mAb BB7.2. All experiments were repeated at least twice
with similar results.
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6

Figure 3.8 MHC-I internalization in BRAF mutant cells is reduced after BRAF
inhibitor treatment.
In our next set of experiments, we sought to determine the intracellular distribution
of MHC-I following MAPK pathway inhibition. The BRAF mutant cell line WM793 was
treated with either DMSO or the BRAFi (dabrafenib) for 2 hours, after which time the
surface MHC-I was labeled with anti-mouse conjugated with W6/32 and the cells were then
placed at 37 degrees for another a further 90 minutes in the presence of DMSO or BRAFi.
After 90 minutes, the cells were stained for remaining surface MHC-I using goat anti-mouse
IgG conjugated to W6/32. The results revealed that the DMSO-treated control cells had less
MHC-I remaining on the cell surface after 90 minutes, compared with the BRAFi-treated
cells, which demonstrated significantly brighter MHC-I surface expression after the same
incubation time (Fig. 3.8A). As shown in the bottom panel of Figure 3.8, a merged image of
total MHC-I (green) and the surface MHC-I (red) is displayed as a yellow color. The
DMSO-treated cell line has less surface class I and more internalized MHC-I. By contrast,
the BRAF-treated cell line has less internalized MHC-I and more surface class I on the cell
surface because of the BRAF treatment.
To quantify the changes in intracellular MHC-I distribution, the program Image J
was used to analyze cells and obtain the average fluorescence pixel intensity of each color
per cell (Fig. 3.8B). The results of the quantification show significant differences in MHC-I
intracellular distribution following BRAFi treatment: more MHC-I surface expression was
seen in BRAFi-treated cells in comparison to the DMSO-treated cells. These results are
consistent with our flow cytometry results and support the notion that MHC-I surface
expression can be regulated by BRAF in melanoma cells.
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Figure 3.8 MHC-I internalization in BRAF mutant cells is reduced after BRAF
inhibitor treatment. (A) BRAF mutant cell line WM793 treated with control DMSO after
a total of 3 hours, surface MHC-I (red), internalized MHC-I (green) and a merged image
(yellow) indicates co-localization of green and red. (B) Quantification of the average pixel
fluorescence per cell of surface MHC-I and internalized MHC-I. The white arrows indicate
internalized class I. All experiments were repeated at least twice with similar results.
Imaging done by Dr. Zeming Chen

70

Figure 3.8

A.

B.
0.0329

Surface MHC-I
Internalized MHC-I
(yellow in merged (green in merged
imaged)
imaged)

: BRAFi
: DMSO

71

CHAPTER IV:
DISCUSSION

72

4.1 Summary
The major aim of this thesis was to first determine the effect of MAPK pathway
inhibitors on MHC-I surface expression. We also sought to determine the role of the MHC-I
cytoplasmic tail in the MAPK pathway modulation of MHC-I surface expression and to
assess any differences in T-cell recognition after MAPK inhibition. We also attempted to
determine the mechanism behind the MAPK pathway regulation of MHC-I surface
expression through observing the steady-state internalization of MHC-I in melanoma cells
and the effects of MAPK pathway inhibitors on internalization. To address these questions,
we compared BRAF mutant cell lines and BRAF WT cell lines, and also used BRAF mutant
melanoma cell lines transduced to express WT-A2 and three cytoplasmic tail mutants. Our
study reveals that the oncogenic MAP kinase pathway can modulate MHC-I surface
expression in BRAF mutant cell lines in a cytoplasmic tail-dependent manner.
We found that MAPK-inhibitor induced modulation of MHC-I surface expression
occurs in BRAF mutant cell lines but does not take place in BRAF WT melanoma cells. Our
studies not only show that the oncogenic MAPK pathway modulates MHC-I surface
expression in a cytoplasmic tail dependent matter, but also appears to be controlled by the
highly conserved serine-335 residue encoded by exon 7 of the MHC-I gene. We showed that
constitutive activation of the MAP kinase pathway in BRAF mutant cell lines leads to an
internalization of MHC-I that can be reversed by inhibition of the pathway. The increase in
surface MHC- I led to a subsequent increase in T-cell recognition and cytokine release. Our
results point to a possible mechanism of immune system evasion by which melanoma cells
with activating BRAF mutations downregulate MHC- I on the cell surface in order to escape
immune recognition and killing.
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4.2 Early effects of MAPK pathway inhibition in melanoma
We have shown that upregulation of MHC-I surface expression takes place following
MAP kinase pathway inhibition (Figures 3.4 and 3.5); these results are supported by
previous reports where MHC-I was also shown to increase on the cell surface in other
melanoma cell lines following MAPK pathway inhibition [67,68]. However, our results
differ significantly with respect to the time points that were analyzed. Both of these reports
demonstrated MHC-I transcriptional upregulation at 24 to 72 hours following drug
treatment, whereas we analyzed much earlier time points (30 minutes to 3 hours) following
drug treatment. We showed that MHC-I upregulation happens much more quickly than
previously reported, and therefore likely occurs independent of transcription. The changes
observed at these early time points suggested a post-translational mechanism, which we
explored further using HLA-A2 containing mutated phosphorylation sites. Although we also
acknowledge that BRAF inhibition induces profound changes in gene expression that can
lead to many downstream changes within the tumor cells, our analysis was performed at
time points that precluded these changes. Previous analysis showed that the BRAF inhibitor
can produce rapidly induced changes that affect more than just MHC-I. For example, a
study by Khalili et al. [19] showed that transduction of melanocytes cells with the BRAF
(V600E)

gene induced the transcription of IL-1 alpha and beta. When the BRAF inhibitor

vemurafenib was used on BRAF mutant cell lines, the level of interleukin 1 alpha and beta
mRNA sharply declined in these cells within 3 to 4 hours. However, changes in protein
expression were not observed until later time points.
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4.3 The role of the cytoplasmic tail in melanoma MHC-I surface expression
The mechanism behind the regulation of MHC-I by the MAP kinase pathway has
remained understudied and the mechanisms poorly understood. In this study, we attempted
to shed more light on this mechanism by looking into the internalization of MHC-I in the
context of a constitutively activated oncogenic MAP kinase pathway. We showed that the
steady-state internalization of MHC-I took place very rapidly in BRAF mutant melanoma
cell lines. Decreases in MHC-I cell surface expression could be detected as early as 30
minutes (Figure 3.5). This constitutive internalization of MHC-I was slowed in melanoma
cells with the BRAFi, but in cells that do not harbor the BRAF mutation, the BRAFi had
little to no effect. Our findings thus are consistent with a model whereby the rapid
internalization of MHC-I is driven by the oncogenic MAP kinase signaling pathway. It
would be of interest to determine the half-life of MHC-I molecules in BRAF mutant cells
before and after BRAFi treatment. If MHC-I protein half-life is stabilized after inhibitor
treatment in melanoma cells, this would be consistent with our results. Alternatively, BRAFi
may not be affecting MHC-I molecular stability, but simply inducing an intracellular
redistribution of MHC-I.
We also showed that the internalization of MHC-I molecules is linked to the MHC-I
cytoplasmic tail. More specifically, the modulation appears to be is linked to the highly
conserved serine-335 encoded by exon 7 of the MHC-I gene. The MHC-I cytoplasmic tail
has already been shown to be involved in endosomal trafficking of MHC-I in dendritic cells.
In contrast to our results, the tyrosine-320 encoded by exon 6 is responsible for this
phenomenon [52]. However, since the MAP kinase pathway is a serine-threonine protein
kinase signaling cascade [74], it makes sense that the serine residue would be the target of
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phosphorylation in these cells and not the tyrosine. If the cytoplasmic serine phosphorylation
site regulates MHC-I surface expression in melanoma cells with BRAF mutations, this raises
the possibility that other oncogenic signaling pathways in other tumors may operate work in
a similar matter. For example, oncogenic KRAS mutations are very common in pancreatic
cancer, and constitutive MAPK activation is a hallmark of many other tumor types [15].
Regardless, we are the first to show that the serine phosphorylation site on the MHC-I
cytoplasmic tail regulates MHC-I surface expression in tumor cells with constitutive MAPK
pathway activation. A working model depicting the potential mechanism behind MHC-I
modulation by oncogenic BRAF in melanoma cells is shown in Figure 4.1.

76

Potential mechanism for the modulation of
MHC-I surface expression

Figure 4.1 Potential mechanism for the modulation of MHC-I surface expression in BRAF
mutant cell lines. Rapid internalization of newly produced MHC-I molecules may be linked to the
phosphorylation of the highly conserved serine located on the MHC-I cytoplasmic tail. MHC-I may
be degraded in lysosomes post internalization or held in early/late endosomes in BRAF mutant cell
lines.
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4.4 The role of BRAF inhibition in CD8+ T-cell recognition
MHC-I molecules play a critical role in CTL-mediated killing of tumor cells. One of
the overall goals of our studies was to connect our observations of MHC-I expression and
discoveries to potential improvements in CTL recognition and killing. The potential impact
of MAPK pathway inhibition in T-cell recognition of melanoma tumors may have the most
important implications for immunotherapy-based cancer treatment. Our results show that
melanoma cells transduced with HLA-A2 point mutants behaved very differently from one
another in terms of inducing T cell recognition; for example, only the WT-A2 and ∆Y-A2
transduced cell lines were able to induce better T-cell recognition after BRAFi treatment. In
these experiments, we showed that CTL-mediated killing can be affected even at early time
points following BRAFi treatment, points and even seemingly small shifts in MHC-I
expression can have significant effects on cytokine production. We observed significant
changes in the amount of IFN gamma released after BRAFi treatment, but it would also be
beneficial to look at the difference in the percentage of tumor cells killed following inhibitor
treatment. In both the ∆T- A2 and ∆S-A2 cell lines, HLA-A2 upregulation does not take
place after treatment with inhibitors at early time points Figure 3.4, thus implicating the
cytoplasmic tail serine-335 residue in the oncogenic pathway MAPK pathway modulation of
MHC-I. It is possible that in all BRAF mutant cell lines, the MHC-I molecules are being
phosphorylated at this highly conserved serine, which then triggers internalization [75].
There is still a lot of information to discover about the role of the MHC-I cytoplasmic in
peptide presentation and anti-tumor immunity. In DCs the removal of exon 7 encoded amino
acids from the MHC-I cytoplasmic tail, which contains the serine-335, contributed to longer
half-life of MHC-I, better T-cell recognition, and anti-tumor immunity [57]. However, Tyr78

320 appears to also be very important for MHC-I trafficking in APCs, suggesting that DCs
and tumor cells may very well behave quite differently from one another in this regard.
Serine-335 may be required in tumor cells for oncogenic induced MHC-I downregulation,
but in DCs tyrosine-320 phosphorylation may be more important for a different aspect of
antigen presentation. These differences show that more studies need to be conducted to
better understand how the MHC-I cytoplasmic tail and MAPK signaling functions in
different cell types, which could help further the development of treatments for cancer
patients.
4.5 Pharmacological Implications
There are still many questions left to answer regarding confirming serine335 as a
potential phosphorylation site, including identifying the exact kinase that may phosphorylate
the serine residue, and whether these findings can be applied to other types of cancers with
oncogenic mutations. The first step to better understand the role of the MHC-I cytoplasmic
tail, is to determine the molecules involved in its function. For example, the phosphatases
and kinases that use the MHC-I cytoplasmic tail as a substrate have yet to be identified. For
our study, if the serine kinase that phosphorylates serine-335 in BRAF mutant cells could be
identified and targeted with a highly specific kinase inhibitor it would be interesting to see if
we would observe the same effects as we saw with the BRAF inhibitor. In addition to Tyr
320 playing a role in trafficking through endosomal compartments of DCs, and Serine (Ser335) playing a role in antigen presentation in tumor cells, there is also a highly conserved
ubiquitination site Lys-316 [76] that may be important for immune system recognition as
well. Identifying the kinases and phosphatases for which the MHC-I cytoplasmic tail is a
substrate could have significant implications for targeted therapy of cancer. If kinase
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inhibitors specific for the serine or tyrosine phosphorylation sites could be discovered they
could be tailored to be used in not just in melanoma treatment but also other types of cancers
that have mutations in oncogenic signaling pathways that affect MHC-I expression. Our
results suggest that it is possible that the oncogene-targeted treatment could be combined
with immunotherapy used to increase T-cell recognition, slow tumor growth, and prevent
metastasis in many types of cancers.
4.6 Future Directions
Perhaps one of the most significant takeaways from this study is the potential
implications that MHC-I modulation by the MAP kinase pathway may have for antigen
presentation. Peptide elutions from tumor cells have been used to discover new melanoma
antigens in the past and to create vaccines [77,78,79]. It would therefore be interesting to
examine the peptides eluted from the cell surface of the melanoma cells before and after
MAPK inhibition. Comparisons can be made about the total number of peptides eluted from
each, the diversity of the peptides, and potentially their function. It would also be interesting
to study the differences in HLA-A2 restricted peptides eluted from cell lines expressing WT
versus tailless HLA-A2. If differences are detected in antigen presentation, T-cells specific
for those antigens could and be possibly exploited as new melanoma target antigens that
would be preferentially expressed in the context of BRAFi treatment.
Further confocal microscopy studies will be required to answer all of the mechanistic
questions this study has raised. We determined that MHC-I is indeed stabilized on the
surface of melanoma cells following MAPK pathway inhibition but there are still more
questions to be answered. For example, which intracellular what compartments do the
MHC-I molecules localize to? Are they being degraded immediately, or simply being
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sequestered within endocytic compartments? Confocal microscopy experiments that label
the surface MHC-I molecules and chase them into the cell, along with co-staining of
intracellular compartments such as early or late endosomes or lysosomes will have to be
done to address these questions. It will also be interesting to characterize whether any
differences are seen between trafficking the cytoplasmic tail and co-localization of the
cytoplasmic tail mutants of HLA-A2.
Combination treatments involving inhibitors with other immunotherapies are
currently being tested in the clinic [80,81]. Several studies, including this one, have
suggested that oncogene targeted therapies and immunotherapies may show synergy [37].
Some new drugs drawing a lot of attention lately are Ipilimumab, an antibody specific for
the negative regulator of T- cells CTLA- 4 [82] and molecules such as check point blockade
antibodies targeting PD-L1 and PD-1 [83]. Alternative signaling pathways closely related to
the MAPK pathway may also be strong candidates for combination therapy, such as the
PTEN/AKT inhibitors [84]. There are many possible drug combinations to be tested and it
will be interesting to determine how MHC-I surface expression and antigen presentation are
affected by these combinations, and more importantly what the implications are for CTLmediated killing of tumor cells.
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